IAS vs. PATH, IONQ, SAIC, VERX, OS, WK, PONY, INTA, BILL, and QTWO
Should you be buying Integral Ad Science stock or one of its competitors? The main competitors of Integral Ad Science include UiPath (PATH), IonQ (IONQ), Science Applications International (SAIC), Vertex (VERX), Onestream (OS), Workiva (WK), Pony AI (PONY), Intapp (INTA), BILL (BILL), and Q2 (QTWO). These companies are all part of the "computer software" industry.
Integral Ad Science vs.
UiPath (NYSE:PATH) and Integral Ad Science (NASDAQ:IAS) are both business services companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, community ranking, institutional ownership, dividends and earnings.
UiPath received 79 more outperform votes than Integral Ad Science when rated by MarketBeat users. However, 52.58% of users gave Integral Ad Science an outperform vote while only 39.27% of users gave UiPath an outperform vote.
In the previous week, Integral Ad Science had 22 more articles in the media than UiPath. MarketBeat recorded 38 mentions for Integral Ad Science and 16 mentions for UiPath. UiPath's average media sentiment score of 0.83 beat Integral Ad Science's score of 0.13 indicating that UiPath is being referred to more favorably in the media.
UiPath has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.Comparatively, Integral Ad Science has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500.
Integral Ad Science has lower revenue, but higher earnings than UiPath. UiPath is trading at a lower price-to-earnings ratio than Integral Ad Science, indicating that it is currently the more affordable of the two stocks.
Integral Ad Science has a net margin of 6.39% compared to UiPath's net margin of -6.49%. Integral Ad Science's return on equity of 3.47% beat UiPath's return on equity.
UiPath presently has a consensus price target of $13.62, indicating a potential upside of 20.09%. Integral Ad Science has a consensus price target of $15.06, indicating a potential upside of 65.81%. Given Integral Ad Science's stronger consensus rating and higher probable upside, analysts plainly believe Integral Ad Science is more favorable than UiPath.
62.5% of UiPath shares are owned by institutional investors. Comparatively, 95.8% of Integral Ad Science shares are owned by institutional investors. 22.4% of UiPath shares are owned by insiders. Comparatively, 2.0% of Integral Ad Science shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Integral Ad Science beats UiPath on 13 of the 18 factors compared between the two stocks.
Get Integral Ad Science News Delivered to You Automatically
Sign up to receive the latest news and ratings for IAS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Integral Ad Science Competitors List
Related Companies and Tools
This page (NASDAQ:IAS) was last updated on 3/26/2025 by MarketBeat.com Staff
